In vitro and in vivo considerations associated with parenteral sustained release products: a review based upon information presented and points expressed at the 2007 Controlled Release Society Annual Meeting.
US Food and Drug Administration, Center for Veterinary Medicine, Office of New Animal Drug Evaluation, Rockville, Maryland 20855, USA. marilyn.martinez@fda.hhs.gov
Marilyn
M
Martinez
Michael
M
Rathbone
Diane
D
Burgess
Mai
M
Huynh
D000818:Animals; D002626:Chemistry, Pharmaceutical; D003692:Delayed-Action Preparations; D004339:Drug Compounding; D004343:Drug Implants; D005079:Excipients / Q000737:chemistry; D006801:Humans; D007263:Infusions, Parenteral; D007700:Kinetics; D008081:Liposomes; D008863:Microspheres; D008954:Models, Biological; D008956:Models, Chemical; D019999:Pharmaceutical Solutions / Q000737:chemistry; D012995:Solubility; D013678:Technology, Pharmaceutical / Q000379:methods*; D019155:Veterinary Drugs / Q000008:administration & dosage / Q000009:adverse effects / Q000737:chemistry / Q000493:pharmacokinetics
D003692:Delayed-Action Preparations; D004343:Drug Implants; D005079:Excipients; D008081:Liposomes; D019999:Pharmaceutical Solutions; D019155:Veterinary Drugs